The future of b-cell lymphoma therapy: The B-cell receptor and its downstream pathways

Vaishalee P. Kenkre, Brad S. Kahl

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3- kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

Original languageEnglish
Pages (from-to)216-220
Number of pages5
JournalCurrent Hematologic Malignancy Reports
Volume7
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Keywords

  • B cell receptor
  • Bruton's tyrosine kinase (BTK)
  • Non-Hodgkin lymphoma
  • Phosphoinositide 3-kinase (PI3K)
  • Spleen tyrosine kinase (Syk)
  • Targeted therapy

Fingerprint Dive into the research topics of 'The future of b-cell lymphoma therapy: The B-cell receptor and its downstream pathways'. Together they form a unique fingerprint.

  • Cite this